Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00310518 | Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma | PHASE2 | COMPLETED | 30 | — | — | Feb 1, 2006 | Jul 1, 2007 | Apr 29, 2009 | 5 | United States |
| NCT00622063 | An Extension Study for Patients Previously Treated With ARQ 501 | PHASE1 | COMPLETED | 1 | — | — | Dec 1, 2006 | - | Feb 28, 2013 | 1 | United States |
| NCT00075933 | ARQ 501 in Subjects With Cancer | PHASE1 | COMPLETED | 80 | — | — | Sep 1, 2003 | Jan 1, 2007 | Apr 28, 2009 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| ARQ 501 | DRUG | - |
Inclusion Criteria: * Able to provide signed and dated informed consent prior to study-specific screening procedures. * Histologically or cytologically confirmed leiomyosarcoma that is persistent, recurrent or metastatic. * Measurable disease as defined by RECIST. * Karnofsky performance status \>=...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |